1-4 of 4
Bernard Fox, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Flotetuzumab (FLZ), an Investigational CD123 x CD3 Bispecific Dart® Protein-Induced Clustering of CD3+ T Cells and CD123+ AML Cells in Bone Marrow Biopsies Is Associated with Response to Treatment in Primary Refractory AML Patients

John E. Godwin, MD, Carmen Ballesteros-Merino, PhD, Nikhil Lonberg, Shawn Jensen, PhD, Tarsem Moudgil, Carlo B Bifulco, MD, Jon Wigginton, MD, John Muth, MS, Jan K Davidson-Moncada, MD PhD, Bernard Fox, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1410.
https://doi.org/10.1182/blood-2019-128485
Published: 2019
Journal Articles

Bone Marrow T Cell Changes By Multiplex IHC after Treatment with Flotetuzumab, a CD123 x CD3 Bispecific Dart ® Protein, in a Primary Refractory t-AML Patient

John Godwin, MD, Carmen Ballesteros-Merino, PhD, Carlo B Bifulco, MD, Helene Lelièvre, PhD PharmD, Jon Wigginton, MD, Jan K Davidson-Moncada, MD PhD, Bernard Fox, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4065.
https://doi.org/10.1182/blood-2018-99-118522
Published: 2018
Journal Articles

Preliminary Translational Results from an Ongoing Phase 1 Study of Flotetuzumab, a CD123 x CD3 Dart®, in AML/MDS: Rationale for Combining Flotetuzumab and Anti-PD-1/PD-L1 Immunotherapies

Michael P Rettig, PhD, John Godwin, MD, Norbert Vey, Bernard Fox, PhD, Carmen Ballesteros-Merino, PhD, Carlo B Bifulco, MD, Daner Li, MS, Daniel Primo, PhD, Joan Ballesteros, PhD, Jichao Sun, PhD, Helene Lelièvre, PhD PharmD, Jan Baughman, MPH, Ross La Motte-Mohs, PhD, John Muth, MS, Paul Moore, PhD, Ezio Bonvini, MD, Jon Wigginton, John F DiPersio, MD PhD, Jan Davidson-Moncada, MDPhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1365.
https://doi.org/10.1182/blood.V130.Suppl_1.1365.1365
Published: 2017
Journal Articles

Preliminary Results of a Phase 1 Study of Flotetuzumab, a CD123 x CD3 Bispecific Dart® Protein, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

Geoffrey L. Uy, MD, John Godwin, MD, Michael P Rettig, PhD, Norbert Vey, Matthew Foster, Martha L. Arellano, MD, David A. Rizzieri, MD, Max S. Topp, MD, Gerwin Huls, MD PhD, Bob Lowenberg, MD PhD, Giovanni Martinelli, MD, Stefania Paolini, MD PhD, Fabio Ciceri, MD, Matteo Giovanni Carrabba, MD, Carmen Ballesteros-Merino, PhD, Carlo B Bifulco, MD, Helene Lelièvre, PhD PharmD, Ross La Motte-Mohs, PhD, Daner Li, MS, Jichao Sun, PhD, Kenneth Jacobs, MD, Karen Spohn, BS, Nadia Lonsdale, BA, Kathy Tran, Jan Baughman, MPH, Michele Shannon, PhD, Bernard Fox, PhD, Ezio Bonvini, MD, Jon Wigginton, Jan Davidson-Moncada, MD, John F DiPersio, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 637.
https://doi.org/10.1182/blood.V130.Suppl_1.637.637
Published: 2017